240 related articles for article (PubMed ID: 22812556)
21. Switching rheumatoid arthritis treatments: an update.
Atzeni F; Sarzi-Puttini P; Gorla R; Marchesoni A; Caporali R
Autoimmun Rev; 2011 May; 10(7):397-403. PubMed ID: 21262393
[TBL] [Abstract][Full Text] [Related]
22. Use of biologics for rheumatoid arthritis tempered by concerns over safety, cost.
Pressman Lovinger S
JAMA; 2003 Jun; 289(24):3229-30. PubMed ID: 12824197
[No Abstract] [Full Text] [Related]
23. Safety issues and concerns of new immunomodulators in rheumatology.
Selmi C; Ceribelli A; Naguwa SM; Cantarini L; Shoenfeld Y
Expert Opin Drug Saf; 2015 Mar; 14(3):389-99. PubMed ID: 25518908
[TBL] [Abstract][Full Text] [Related]
24. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.
Askling J; Fored CM; Baecklund E; Brandt L; Backlin C; Ekbom A; Sundström C; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L; Feltelius N
Ann Rheum Dis; 2005 Oct; 64(10):1414-20. PubMed ID: 15843454
[TBL] [Abstract][Full Text] [Related]
25. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases.
Taylor PC
Curr Opin Pharmacol; 2010 Jun; 10(3):308-15. PubMed ID: 20172761
[TBL] [Abstract][Full Text] [Related]
26. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
Prescrire Int; 2010 Feb; 19(105):30-4. PubMed ID: 20455343
[TBL] [Abstract][Full Text] [Related]
27. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
[TBL] [Abstract][Full Text] [Related]
28. TNF inhibitors - new and old agents for rheumatoid arthritis.
Simsek I
Bull NYU Hosp Jt Dis; 2010; 68(3):204-10. PubMed ID: 20969553
[TBL] [Abstract][Full Text] [Related]
29. Comparative effectiveness of biologic antirheumatic therapies in rheumatoid arthritis after failure to respond to a first TNF inhibitor.
Finckh A
J Comp Eff Res; 2012 Nov; 1(6):481-4. PubMed ID: 24236466
[TBL] [Abstract][Full Text] [Related]
30. Biologics in rheumatoid arthritis.
Sharma PK; Hota D; Pandhi P
J Assoc Physicians India; 2004 Mar; 52():231-6. PubMed ID: 15636315
[TBL] [Abstract][Full Text] [Related]
31. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab.
Fleischmann RM
Semin Arthritis Rheum; 2009 Feb; 38(4):265-80. PubMed ID: 18336874
[TBL] [Abstract][Full Text] [Related]
32. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.
Nurmohamed MT; Dijkmans BA
Drugs; 2005; 65(5):661-94. PubMed ID: 15748099
[TBL] [Abstract][Full Text] [Related]
33. Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011?
Singer O; Gibofsky A
Curr Opin Rheumatol; 2011 May; 23(3):288-92. PubMed ID: 21378570
[TBL] [Abstract][Full Text] [Related]
34. A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis.
Mandema JW; Salinger DH; Baumgartner SW; Gibbs MA
Clin Pharmacol Ther; 2011 Dec; 90(6):828-35. PubMed ID: 22048227
[TBL] [Abstract][Full Text] [Related]
35. Innovative treatment strategies for patients with rheumatoid arthritis.
van der Kooij SM; Allaart CF; Dijkmans BA; Breedveld FC
Curr Opin Rheumatol; 2008 May; 20(3):287-94. PubMed ID: 18388520
[TBL] [Abstract][Full Text] [Related]
36. [Proposal for anti-TNFalpha therapy in adult patients with rheumatoid arthritis].
Curković B; Babić-Naglić D; Morović-Vergles J; Anić B; Grazio S
Reumatizam; 2007; 54(1):16-9. PubMed ID: 18450272
[TBL] [Abstract][Full Text] [Related]
37. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care.
Curtis JR; Singh JA
Clin Ther; 2011 Jun; 33(6):679-707. PubMed ID: 21704234
[TBL] [Abstract][Full Text] [Related]
38. To switch or to change class-the biologic dilemma in rheumatoid arthritis.
Villeneuve E; Haraoui B
Nat Rev Rheumatol; 2010 May; 6(5):301-5. PubMed ID: 20386564
[TBL] [Abstract][Full Text] [Related]
39. The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy.
Tarnowski M; Paradowska-Gorycka A; Dąbrowska-Zamojcin E; Czerewaty M; Słuczanowska-Głąbowska S; Pawlik A
Expert Opin Drug Metab Toxicol; 2016; 12(1):41-55. PubMed ID: 26609565
[TBL] [Abstract][Full Text] [Related]
40. Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis.
Rajakulendran S; Gadsby K; Allen D; O'Reilly S; Deighton C
Ann Rheum Dis; 2006 Dec; 65(12):1678-9. PubMed ID: 17105865
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
